NAD(+)-boosting therapy alleviates nonalcoholic fatty liver disease via stimulating a novel exerkine Fndc5/irisin

Rationale: Nicotinamide adenine dinucleotide(+) (NAD(+))-boosting therapy has emerged as a promising strategy to treat various health disorders, while the underlying molecular mechanisms are not fully understood. Here, we investigated the involvement of fibronectin type III domain containing 5 (Fndc...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Dong-Jie, Sun, Si-Jia, Fu, Jiang-Tao, Ouyang, Shen-Xi, Zhao, Qin-Jie, Su, Li, Ji, Qing-Xi, Sun, Di-Ynag, Zhu, Jia-Hui, Zhang, Guo-Yan, Ma, Jia-Wei, Lan, Xiu-Ting, Zhao, Yi, Tong, Jie, Li, Guo-Qiang, Shen, Fu-Ming, Wang, Pei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7977447/
https://www.ncbi.nlm.nih.gov/pubmed/33754067
http://dx.doi.org/10.7150/thno.53652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7977447/
https://www.ncbi.nlm.nih.gov/pubmed/33754067
http://dx.doi.org/10.7150/thno.53652

Ejemplares similares